NASDAQ:NEXI

Neximmune Stock Insider Trading

Healthcare > Biotechnology

Buy NEXI

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Jul 31, 2026

NexImmune Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 2.02M and sold 1.74M NEXI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	2.02M shares
● Sell	1.74M shares
64% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Yao Zhengbin Director	Director	9 556 Value: $15.7K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Yao Zhengbin Director	Director	23 122 Value: $99.7K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Yao Zhengbin Director	Director	61 678 Value: $112.3K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Yao Zhengbin Director	Director	9 556 Value: $162.5K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	D'angio Paul Director	Director	61 678 Value: $101.2K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	D'angio Paul Director	Director	23 122 Value: $37.9K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	D'angio Paul Director	Director	12 634 Value: $20.7K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	D'angio Paul Director	Director	9 556 Value: $15.7K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	D'angio Paul Director	Director	23 122 Value: $99.7K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	D'angio Paul Director	Director	9 556 Value: $162.5K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	D'angio Paul Director	Director	12 634 Value: $30.6K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	D'angio Paul Director	Director	61 678 Value: $112.3K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Bertram Timothy Director	Director	61 678 Value: $101.2K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Bertram Timothy Director	Director	23 122 Value: $37.9K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Bertram Timothy Director	Director	12 634 Value: $20.7K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Bertram Timothy Director	Director	12 634 Value: $30.6K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Bertram Timothy Director	Director	9 556 Value: $15.7K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Barer Sol J Director	Director	19 113 Value: $324.9K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Barer Sol J Director	Director	61 678 Value: $101.2K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Barer Sol J Director	Director	155 900 Value: $255.7K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Bertram Timothy Director	Director	9 556 Value: $162.5K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Barer Sol J Director	Director	61 678 Value: $112.3K
Apr 04, 2023 Sell	Stock Option (right to buy) D-Return	Oelke Mathias Chief Science Officer	Officer	31 948 Value: $137.7K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Oelke Mathias Chief Science Officer	Officer	4 755 Value: $6K
Apr 04, 2023 Buy	Stock Option (right to buy) A-Award	Oelke Mathias Chief Science Officer	Officer	12 855 Value: $15.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NEXIMMUNE, INC.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials f...

Read Full Profile Here